GlassScriptPhysician profile
Carline Brownlee
NPI 1154885440
$2,982.03
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,463 · 2022: $79.68 · 2023: $204 · 2024: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $385 · Education: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $385.48 |
| Education | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $647.66 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $328.19 | 2023-2024 | Austedo Xr, Austedo |
| Sanofi-Aventis U.S. LLC | $308.77 | 2021 | |
| Glaxosmithkline, LLC. | $282.65 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $245.60 | 2021 | |
| Novo Nordisk INC | $204.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $180.97 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.99 | 2021 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Nestle Healthcare Nutrition INC. | $108.30 | 2021 | |
| Lilly USA, LLC | $65.03 | 2021 | |
| Gilead Sciences, INC. | $60.55 | 2021 | |
| Neurocrine Biosciences, INC. | $57.29 | 2023 | Ingrezza |
| Medtronic, INC. | $54.00 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $24.49 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carline Brownlee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.